In particular, pimobendan has been shown to decrease the production of intracardiac IL-1β, IL-6, TNF-α and nitric oxide [59] by inhibiting the activation of NFκB [60] in mouse models of heart failure. This evidence concerns the gene IL1B and heart failure.